ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 340,47
-0,72%
Dow Jones
42 392,27
-0,36%
DAX
19 962,76
-0,21%
Brent Oil
75,745
-0,15%
Bitcoin
96 778,54
-0,12%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Atea Pharmaceuticals Inc (AVIR)

  7. Atea Pharmaceuticals Inc (AVIR) Actualités

AVIR

Atea Pharmaceuticals (AVIR)

Atea Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AVIR
DateHeureSourceTitreSymboleSociété
16/12/202411h00GlobeNewswire Inc.Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic PartnershipsNASDAQ:AVIRAtea Pharmaceuticals Inc
04/12/202413h00GlobeNewswire Inc.Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)NASDAQ:AVIRAtea Pharmaceuticals Inc
26/11/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
20/11/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AVIRAtea Pharmaceuticals Inc
15/11/202417h00GlobeNewswire Inc.Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
07/11/202422h41Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVIRAtea Pharmaceuticals Inc
07/11/202422h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVIRAtea Pharmaceuticals Inc
07/11/202422h05GlobeNewswire Inc.Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
31/10/202412h00GlobeNewswire Inc.Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
30/10/202412h00GlobeNewswire Inc.Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
19/09/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
13/09/202413h00GlobeNewswire Inc.Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19NASDAQ:AVIRAtea Pharmaceuticals Inc
28/08/202413h00GlobeNewswire Inc.Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation PathwayNASDAQ:AVIRAtea Pharmaceuticals Inc
07/08/202422h05GlobeNewswire Inc.Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
31/07/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
18/06/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
05/06/202413h00GlobeNewswire Inc.Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
04/06/202422h15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AVIRAtea Pharmaceuticals Inc
29/05/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
22/05/202413h00GlobeNewswire Inc.Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202422h05GlobeNewswire Inc.Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
07/05/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
29/04/202413h00GlobeNewswire Inc.Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
27/03/202412h00GlobeNewswire Inc.Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsNASDAQ:AVIRAtea Pharmaceuticals Inc
28/02/202422h05GlobeNewswire Inc.Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
21/02/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
08/01/202422h05GlobeNewswire Inc.Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19NASDAQ:AVIRAtea Pharmaceuticals Inc
03/01/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
13/11/202313h00GlobeNewswire Inc.Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
08/11/202322h05GlobeNewswire Inc.Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AVIR

Dernières Valeurs Consultées

USI
USTECH100
US Tech 100
NASDAQ
AAPL
Apple
EU
VIV
Vivendi
EU
PX4
SBF 120
EU
PX1
CAC 40
EU
CS
Axa
EU
BEL20
Bel 20
EU
DG
Vinci
COIN
ETHUSD
Ethereum
EU
RNO
Renault
EU
VK
Vallourec
EU
AF
Air FranceKLM
EU
ACA
Credit Agricole
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés